Cost effectiveness of school-located influenza vaccination programs for elementary and secondary school children

Byung-Kwang Yoo, Stanley J Schaffer, Sharon G Humiston, Cynthia M Rand, Nicolas P N Goldstein, Christina S Albertin, Cathleen Concannon, Peter G Szilagyi, Byung-Kwang Yoo, Stanley J Schaffer, Sharon G Humiston, Cynthia M Rand, Nicolas P N Goldstein, Christina S Albertin, Cathleen Concannon, Peter G Szilagyi

Abstract

Background: Studies have noted variations in the cost-effectiveness of school-located influenza vaccination (SLIV), but little is known about how SLIV's cost-effectiveness may vary by targeted age group (e.g., elementary or secondary school students), or vaccine consent process (paper-based or web-based). Further, SLIV's cost-effectiveness may be impacted by its spillover effect on practice-based vaccination; prior studies have not addressed this issue.

Methods: We performed a cost-effectiveness analysis on two SLIV programs in upstate New York in 2015-2016: (a) elementary school SLIV using a stepped wedge design with schools as clusters (24 suburban and 18 urban schools) and (b) secondary school SLIV using a cluster randomized trial (16 suburban and 4 urban schools). The cost-per-additionally-vaccinated child (i.e., incremental cost-effectiveness ratio (ICER)) was estimated by dividing the incremental SLIV intervention cost by the incremental effectiveness (i.e., the additional number of vaccinated students in intervention schools compared to control schools). We performed deterministic analyses, one-way sensitivity analyses, and probabilistic analyses.

Results: The overall effectiveness measure (proportion of children vaccinated) was 5.7 and 5.5 percentage points higher, respectively, in intervention elementary (52.8%) and secondary schools (48.2%) than grade-matched control schools. SLIV programs vaccinated a small proportion of children in intervention elementary (5.2%) and secondary schools (2.5%). In elementary and secondary schools, the ICER excluding vaccine purchase was $85.71 and $86.51 per-additionally-vaccinated-child, respectively. When additionally accounting for observed spillover impact on practice-based vaccination, the ICER decreased to $80.53 in elementary schools -- decreasing substantially in secondary schools. (to $53.40). These estimates were higher than the published practice-based vaccination cost (median = $25.50, mean = $45.48). Also, these estimates were higher than our 2009-2011 urban SLIV program mean costs ($65) due to additional costs for use of a new web-based consent system ($12.97 per-additionally-vaccinated-child) and higher project coordination costs in 2015-2016. One-way sensitivity analyses showed that ICER estimates were most sensitive to the SLIV effectiveness.

Conclusions: SLIV raises vaccination rates and may increase practice-based vaccination in primary care practices. While these SLIV programs are effective, to be as cost-effective as practice-based vaccination our SLIV programs would need to vaccinate more students and/or lower the costs for consent systems and project coordination.

Trial registration: ClinicalTrials.gov NCT02227186 (August 25, 2014), updated NCT03137667 (May 2, 2017).

Keywords: Adolescents; Cost-effectiveness analysis; Incremental cost-effectiveness ratio; Influenza vaccination; School-age children; School-located vaccination program; Web-based consent form system.

Conflict of interest statement

SH’s institution received grant support from the Pfizer Foundation at the time of data analysis. Other authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Decision tree model to conduct a cost effectiveness analysis for school-located influenza vaccination program in 2015–2016, accounting for potential spillover. Model parameters are defined in Table 2; # is a probability defined by other parameters so that each chance node (○ in the tree) has the summed probability of 1
Fig. 2
Fig. 2
Decision tree model to conduct a cost effectiveness analysis for school-located influenza vaccination program in 2015–2016, without accounting for potential spillover. Model parameters are defined in Table 2; # is a probability defined by other parameters so that each chance node (○ in the tree) has the summed probability of 1

References

    1. Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Bresee JS, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2017-18 influenza season. MMWR Recomm Rep. 2017;66(2):1–20. doi: 10.15585/mmwr.rr6602a1.
    1. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086–5096. doi: 10.1016/j.vaccine.2007.03.046.
    1. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, Bresee JS, Cox NS. Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP), 2008. MMWR Recomm Rep. 2008;57(RR-7):1–60.
    1. Centers for Disease Control and Prevention (CDC) Flu Vaccination Coverage, United States, 2016–17 Influenza Season. 2017.
    1. Rand CM, Szilagyi PG, Yoo BK, Auinger P, Albertin C, Coleman MS. Additional visit burden for universal influenza vaccination of US school-aged children and adolescents. Arch Pediatr Adolesc Med. 2008;162(11):1048–1055. doi: 10.1001/archpedi.162.11.1048.
    1. Humiston SG, Poehling KA, Szilagyi PG. School-located influenza vaccination: can collaborative efforts go the distance? Acad Pediatr. 2014;14(3):219–220. doi: 10.1016/j.acap.2014.03.004.
    1. Keane VA, Hudson AR, King JC. Pediatrician attitudes concerning school-located vaccination clinics for seasonal influenza. Pediatrics. 2012;129(Suppl 2):S96–S100. doi: 10.1542/peds.2011-0737I.
    1. Kempe A, Wortley P, O'Leary S, Crane LA, Daley MF, Stokley S, Babbel C, Dong F, Beaty B, Seewald L, Suh C, Dickinson LM. Pediatricians' attitudes about collaborations with other community vaccinators in the delivery of seasonal influenza vaccine. Acad Pediatr. 2012;12(1):26–35. doi: 10.1016/j.acap.2011.07.004.
    1. Middleman AB, Short MB, Doak JS. School-located influenza immunization programs: factors important to parents and students. Vaccine. 2012;30(33):4993–4999. doi: 10.1016/j.vaccine.2012.05.022.
    1. Santibanez TA, Vogt TM, Zhai Y, McIntyre AF. Place of influenza vaccination among children--United States, 2010-11 through 2013-14 influenza seasons. Vaccine. 2016;34(10):1296–1303. doi: 10.1016/j.vaccine.2016.01.032.
    1. Cawley J, Hull HF, Rousculp MD. Strategies for implementing school-located influenza vaccination of children: a systematic literature review. J Sch Health. 2010;80(4):167–175. doi: 10.1111/j.1746-1561.2009.00482.x.
    1. Hull HF, Ambrose CS. Current experience with school-located influenza vaccination programs in the United States: a review of the medical literature. Hum Vaccin. 2011;7(2):153–160. doi: 10.4161/hv.7.2.13668.
    1. Humiston S, Schaffer S, Szilagyi P, Long C, Chappel T, Blumkin A, Szydlowski J, Kolasa M. Seasonal influenza vaccination at school: a randomized controlled trial. Am J Prev Med. 2014;46(1):1–9. doi: 10.1016/j.amepre.2013.08.021.
    1. Szilagyi Peter G., Schaffer Stanley, Rand Cynthia M., Vincelli Phyllis, Eagan Ashley, Goldstein Nicolas P.N., Hightower A. Dirk, Younge Mary, Blumkin Aaron, Albertin Christina S., Yoo Byung-Kwang, Humiston Sharon G. School-Located Influenza Vaccinations: A Randomized Trial. Pediatrics. 2016;138(5):e20161746. doi: 10.1542/peds.2016-1746.
    1. Szilagyi PG, Schaffer S, Rand CM, Goldstein NPN, Vincelli P, Hightower AD, Younge M, Eagan A, Blumkin A, Albertin CS, DiBitetto K, Yoo BK, Humiston SG. School-located influenza vaccinations for adolescents: a randomized controlled trial. J Adolesc Health. 2018;62(2):157–163. doi: 10.1016/j.jadohealth.2017.09.021.
    1. Szilagyi PG, Schaffer S, Rand CM, Goldstein NPN, Hightower AD, Younge M, Eagan A, Blumkin A, Albertin CS, DiBitetto K, Concannon C, Vincelli P, Yoo BK, Humiston SG. Impact of elementary school-located influenza vaccinations: a stepped wedge trial across a community. Vaccine. 2018;36(20):2861–2869. doi: 10.1016/j.vaccine.2018.03.047.
    1. Yoo BK, Humiston SG, Szilagyi PG, Schaffer SJ, Long C, Kolasa M. Cost effectiveness analysis of elementary school-located vaccination against influenza--results from a randomized controlled trial. Vaccine. 2013;31(17):2156–2164. doi: 10.1016/j.vaccine.2013.02.052.
    1. Yoo BK, Humiston SG, Szilagyi PG, Schaffer SJ, Long C, Kolasa M. Cost effectiveness analysis of year 2 of an elementary school-located influenza vaccination program-results from a randomized controlled trial. BMC Health Serv Res. 2015;15:511. doi: 10.1186/s12913-015-1169-5.
    1. Yoo BK, Szilagyi PG, Schaffer SJ, Humiston SG, Rand CM, Albertin CS, Vincelli P, Blumkin AK, Shone LP, Coleman MS. Cost of universal influenza vaccination of children in pediatric practices. Pediatrics. 2009;124(Suppl 5):S499–S506. doi: 10.1542/peds.2009-1542I.
    1. Schmier J, Li S, King JC, Jr, Nichol K, Mahadevia PJ. Benefits and costs of immunizing children against influenza at school: an economic analysis based on a large-cluster controlled clinical trial. Health Aff (Millwood) 2008;27(2):w96–104. doi: 10.1377/hlthaff.27.2.w96.
    1. Hull HF, Frauendienst RS, Gundersen ML, Monsen SM, Fishbein DB. School-based influenza immunization. Vaccine. 2008;26(34):4312–4313. doi: 10.1016/j.vaccine.2008.06.015.
    1. Effler PV, Chu C, He H, Gaynor K, Sakamoto S, Nagao M, Mendez L, Park SY. Statewide school-located influenza vaccination program for children 5-13 years of age, Hawaii, USA. Emerg Infect Dis. 2010;16(2):244–250. doi: 10.3201/eid1602.091375.
    1. Kempe A, Daley MF, Pyrzanowski J, Vogt T, Fang H, Rinehart DJ, Morgan N, Riis M, Rodgers S, McCormick E, Hammer A, Campagna EJ, Kile D, Dickinson M, Hambidge SJ, Shlay JC. School-located influenza vaccination with third-party billing: outcomes, cost, and reimbursement. Acad Pediatr. 2014;14(3):234–240. doi: 10.1016/j.acap.2014.01.005.
    1. Kwong JC, Pereira JA, Quach S, Pellizzari R, Dusome E, Russell ML, Hamid JS, Feinberg Y, Winter A-L, Gubbay JB, Sirtonski B, Moher D, Sider D, Finkelstein M, Loeb M. Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) pilot study: a cluster randomized trial. Vaccine. 2015;33(4):535–541. doi: 10.1016/j.vaccine.2014.11.044.
    1. Orenstein WA, Schaffner W. Lessons learned: role of influenza vaccine production, distribution, supply, and demand--what it means for the provider. Am J Med. 2008;121(7 Suppl 2):S22–S27. doi: 10.1016/j.amjmed.2008.05.004.
    1. Schuller KA, Probst JC. Factors associated with influenza vaccination among US children in 2008. J Infect Public Health. 2013;6(2):80–88. doi: 10.1016/j.jiph.2012.12.001.
    1. School Nutrition Association. School Meal Trends & Stats. . Accessed 2 Feb 2019.
    1. Kaiser Family Foundation. Distribution of Total Population by Federal Poverty Level. . Accessed 2 Feb 2019.
    1. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care Programmes. 4th ed. Oxford University Press; 2015.
    1. Prosser LA, Bridges CB, Uyeki TM, Hinrichsen VL, Meltzer MI, Molinari NA, Schwartz B, Thompson WW, Fukuda K, Lieu TA. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis. 2006;12(10):1548–1558. doi: 10.3201/eid1210.051015.
    1. Luce BR, Manning WG, Siegel JE, Lipscomb J, Weinstein MC. Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, editors. Cost-Effectiveness in Health and Medicine. USA: Oxford University Press; 1996. pp. 176–183.
    1. U.S. Bureau of Labor Statistics . Occupational employment statistics: May 2009 National Occupational Employment and Wage Estimates, United States. 2010.
    1. Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States. Vaccine. 2008;26(23):2841–2848. doi: 10.1016/j.vaccine.2008.03.046.
    1. Cho BH, Asay GR, Lorick SA, Tipton ML, Dube NL, Messonnier ML. Costs of school-located influenza vaccination clinics in Maine during the 2009-2010 H1N1 pandemic. J Sch Nurs. 2012;28(5):336–343. doi: 10.1177/1059840512457049.
    1. Kansagra SM, McGinty MD, Morgenthau BM, Marquez ML, Rosselli-Fraschilla A, Zucker JR, Farley TA. Cost comparison of 2 mass vaccination campaigns against influenza a H1N1 in new York City. Am J Public Health. 2012;102(7):1378–1383. doi: 10.2105/AJPH.2011.300363.
    1. U.S. Bureau of Labor Statistics (BLS). Table 24. Historical consumer Price index for all urban consumers (CPI-U): U. S. city average, all items. 2018. . Accessed 11 May 2018.
    1. U.S. Bureau of Labor Statistics (BLS). May 2015 National Occupational Employment and Wage Estimates United States 2016. . Accessed 11 May 2018.
    1. Asay GR, Cho BH, Lorick SA, Tipton ML, Dube NL, Messonnier ML. Coordination costs for school-located influenza vaccination clinics, Maine, 2009 H1N1 pandemic. J Sch Nurs. 2012;28(5):328–335. doi: 10.1177/1059840512448676.
    1. King JC, Stoddard JJ, Gaglani MJ, Moore KA, Magder L, McClure E, Rubin JD, Englund JA, Neuzil K. Effectiveness of school-based influenza vaccination. N Engl J Med. 2006;355(24):2523–2532. doi: 10.1056/NEJMoa055414.
    1. Pannaraj PS, Wang HL, Rivas H, Wiryawan H, Smit M, Green N, Aldrovandi GM, El Amin AN, Mascola L. School-located influenza vaccination decreases laboratory-confirmed influenza and improves school attendance. Clin Infect Dis. 2014;59(3):325–332. doi: 10.1093/cid/ciu340.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅